

# Effects of a nutrient dense infant formula on the growth and tolerance of infants compared to current practice in Spain.

Gepubliceerd: 30-01-2008 Laatste bijgewerkt: 18-08-2022

A nutrient dense infant formula promotes growth more effectively than current practice.

|                             |                       |
|-----------------------------|-----------------------|
| <b>Ethische beoordeling</b> | Positief advies       |
| <b>Status</b>               | Werving gestopt       |
| <b>Type aandoening</b>      | -                     |
| <b>Onderzoekstype</b>       | Interventie onderzoek |

## Samenvatting

### ID

NL-OMON29641

### Bron

NTR

### Verkorte titel

INGROTO

### Aandoening

(non-) organic growth failure

## Ondersteuning

**Primaire sponsor:** Numico Research B.V.

**Overige ondersteuning:** Numico Research B.V.

## Onderzoeksproduct en/of interventie

## Uitkomstmaten

### Primaire uitkomstmaten

Increase in Z-score for length at 6 weeks relative to baseline.

# Toelichting onderzoek

## Achtergrond van het onderzoek

The aim of this study is to compare the effects, with regard to growth, of a nutrient dense infant formula to the effect of current practice in Spain in infants requiring a high-energy feed. Therefore, subjects will receive either a nutrient dense infant formula or current practice for a period of 6 weeks. An optional 6-week extension period is offered to all subjects completing the initial 6-week study period. Baseline anthropometrics measurements will be collected and repeated outcomes will be measured during hospital visits at week 3, 6, 9, and 12. Tolerance to the feed will be recorded weekly and a 3-day food diary will be completed to evaluate the intake of other foods/drinks. Subject's blood and stool samples will be collected at baseline, 6 weeks, and 12 weeks for the analysis of safety parameters and fecal microbiota respectively.

## Doel van het onderzoek

A nutrient dense infant formula promotes growth more effectively than current practice.

## Onderzoeksopzet

Baseline, and follow up measurements at 3 weeks, 6 weeks (and 9 weeks and 12 weeks, in case of optional extension period) after baseline.

## Onderzoeksproduct en/of interventie

Duration intervention: 6-12 weeks. Intervention group: a high energy, high protein and nutrient dense, nutritionally complete, ready-to-use feed for infants 0-12 months. Control group: constitutes all infant formulas used as part of "current practice" in Spain for infants with increased energy requirements and/or fluid restrictions.

# Contactpersonen

## Publiek

Numico Research B.V.  
PO Box 7005

Mieke Roelofs  
Wageningen 6700 CA

The Netherlands  
+31 (0)317 467 884

## **Wetenschappelijk**

Numico Research B.V.  
PO Box 7005

Mieke Roelofs  
Wageningen 6700 CA  
The Netherlands  
+31 (0)317 467 884

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

1. Infants aged 0 to 9 months;
2. Infants with increased energy requirements and/or fluid restrictions and/or with indication for using high-energy feeds;
3. The infants must be new consumers of oral high-energy feeds;
4. Infants must have an expected requirement for the study product for at least 6 weeks, with an expected study product intake of, on average, at least 50% of their energy intake;
5. Written parental informed consent must be available.

### **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

1. Infants with cow's milk intolerance, major gastrointestinal hepatic or renal dysfunction, or inherited metabolic disorders including galactosaemia are excluded for this study;
2. Investigator's uncertainty about the willingness or ability of the caretaker to comply with the protocol requirements;
3. Participation in any other studies with investigational or marketed products concomitantly

or within two weeks prior to entry into this study.

## Onderzoeksopzet

### Opzet

|                  |                         |
|------------------|-------------------------|
| Type:            | Interventie onderzoek   |
| Onderzoeksmodel: | Parallel                |
| Toewijzing:      | Gerandomiseerd          |
| Blinding:        | Open / niet geblindeerd |
| Controle:        | Geneesmiddel            |

### Deelname

|                         |                       |
|-------------------------|-----------------------|
| Nederland               |                       |
| Status:                 | Werving gestopt       |
| (Verwachte) startdatum: | 01-02-2008            |
| Aantal proefpersonen:   | 80                    |
| Type:                   | Werkelijke startdatum |

## Ethische beoordeling

|                 |                  |
|-----------------|------------------|
| Positief advies |                  |
| Datum:          | 30-01-2008       |
| Soort:          | Eerste indiening |

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

## Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

## In overige registers

| Register       | ID                                 |
|----------------|------------------------------------|
| NTR-new        | NL1156                             |
| NTR-old        | NTR1199                            |
| Ander register | Numico Research B.V. : 100.153     |
| ISRCTN         | ISRCTN wordt niet meer aangevraagd |

## Resultaten

### Samenvatting resultaten

N/A